As a cautious swimmer slips slowly into the cool waters of a giant swimming pool so do biopharma executives: They tread into the murky abyss known as artificial intelligence (AI). Read More
Artificial intelligence (AI) is a technology that takes over when the human brain has reached its limit. For medical technology companies, it could help in the creation of more precise tools and devices that support diagnostic, therapeutic and surgical decisions. Instead of shooting an arrow into the sky, the bullseye target is clear, backed up by volumes of data and a machine learning algorithm designed to pinpoint the biomarker, the abnormality and the probability of success. Read More
Graybug Vision Inc., a Redwood City, Calif.-based company developing therapies for eye diseases, has secured $80 million in series C financing to support moving its lead candidate, GB-102, into midstage studies in both wet age-related macular degeneration (AMD) and macular edema. Read More
Oncorus Inc. plans to use its oversubscribed $79.5 million series B financing getting its lead candidate, ONCR-177, into the clinic early next year. Read More
LONDON – Themis Bioscience GmbH has landed an exclusive licensing deal with Merck & Co. Inc., which simultaneously validates its measles virus-based vaccines platform and provides the means to extend the technology to new indications. Read More
South Korean biotech Toolgen Inc., based in Seoul, has signed an agreement with another Korean biomedical startup, Nsage Inc., based in Incheon, to cooperate on gene-edited cell line R&D and commercialization. Read More
It wouldn't take an act of the U.S. Congress or even an executive order for the Centers for Medicare & Medicaid Services (CMS) to save millions of dollars on Medicare Part B drugs. Read More
Tonix Pharmaceuticals Holding Corp., of New York, is collaborating with Massachusetts General Hospital to develop TNX-1500, a monoclonal antibody targeting CD154, for the prevention and treatment of organ transplant rejection. Read More
Therapeuticsmd Inc., of Boca Raton, Fla., agreed to pay $200,000 in a civil penalty but admitted no wrongdoing in response to an SEC order charging it with violating Regulation FD based on selective disclosures about the company's dealings with the FDA. Read More
The convergence of artificial intelligence (AI) and the health care sector was inevitable. The advent of machine-learning and deep-learning technologies capable of analyzing and synthesizing massive amounts of data with algorithms designed to mimic human-level decision-making seems a natural fit for an industry in dire need of greater efficiency. Read More
